Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of epcoritamab alone or with standard therapy in Chinese adults with B-cell non-Hodgkin lymphoma
CTR20220331Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma (FL), sponsored by AbbVie Inc.. Started May 2022; status: active.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20220331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220331.